Dabigatran resulted in an
approximately three-fold increase in bleeding time, consistent with
supratherapeutic dabigatran plasma levels. Beriplex (35 and 50 IU/kg),
Octaplex (40 IU/kg), Profilnine (50 IU/kg), Bebulin (60 IU/kg), Factor
Eight Inhibitor Bypassing Activity (100 U/kg), and NovoSeven (500 μg/kg)
significantly decreased this prolonged bleeding time over 30 min (P < 0.001). The coagulation assays were prolonged three- to eight-fold over baseline (P
= 0.01). None of the CFCs produced a consistent change in these assays
that was predictive of reduced bleeding. Thrombin generation reversal
was dependent on the concentration of dabigatran and each CFC;
normalization occurred at the lower concentration of dabigatran with
most CFCs, but not at higher concentrations.
Conclusions: In this animal
model, bleeding induced by high doses of dabigatran can be reduced by
CFCs. However, routine coagulation assays do not predict this effect.